

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
--2020--			
Dan Buchanan	University of Melbourne	Phase V CORE Somatic BRAF and KRAS testing	C-CP-0120-01
Dan Buchanan	University of Melbourne	Phase V CORE germline MMR & MYH mutation testing	C-CP-0120-02
Dan Buchanan	University of Melbourne	Phase V CORE MLH1 promoter methylation testing	C-CP-0120-03
Barbara Connell	Biocartis	Biocartis Study - Diagnostic Accuracy Study Idylla™ MSI Test v2.0	C-EX-0120-01
--2019--			
Yanxin Luo	Sixth Affiliated Hospital, Sun Yat-sen University	DNA Methylation Signatures and Recurrence in Early-stage Colorectal Cancer	C-EX-0219-01
Robert Gryfe	Sinai Health System	Characterizing the role of the Commensal Flora in Colon Cancer	C-TO-0219-01
James Dowty	Univeristy of Melbourne	Heritable methylation marks associated with colorectal cancer risk.	C-AU-0319-02
Mark Jenkins	Univeristy of Melbourne	Does the association between BMI (and height) and colorectal cancer risk differ by degree of family history of colorectal cancer?	C-AU-0319-01
Mark Jenkins	Univeristy of Melbourne	DEPTH: A Novel Algorithm for Feature Ranking with Applica	C-AU-1019-01
Christopher Li	Fred Hutchinson Cancer Research Center	Etiology and biology of site-specific metastases	C-EX-0219-02
--2018--			
Patrick Bradshaw	University of California, Berkeley	Exogenous Estrogens, Reproductive History and CRC.	C-LA-0213-01
Darren Brenner	University of Calgary	Mutational Signatures in Young Onset CRC: A Pilot Study	C-EX-1018-01
Daniel Buchanan	University of Melbourne	Building a tumorigenesis atlas to personalise the risk of colon cancer in people with Lynch syndrome.	C-AU-0818-01
Daniel Buchanan	University of Melbourne	Phase IV Core CCFR gMMR testing.	C-CP-1217-01-A1
Steven Gallinger	Sinai Health System	Cancer Research UK (CRUK) Mutographs of Cancer: Discovering the Causes of Cancer through Mutational Signatures	C-TO-1018-01
Steven Gallinger	Sinai Health System	Association between Lysosomal Storage Disorder Gene and Pancreatic cancer	C-TO-1118-01
Robert Gryfe	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	Next-generation sequencing classification of variants of unknown significance in Lynch syndrome.	C-TO-0318-01
John Hopper	University of Melbourne	Estimating the average CRC risks for the MMR gene variants in each category of the InSiGHT five-tiered classification system.	C-AU-1118-01
Xinwei Hua	Fred Hutchinson Cancer Research Center	Inflammatory biomarkers genes, and CRC survival.	C-SE-0618-01
Holli Loomans	National Cancer Institute	Frameshift mutation detection in Lynch syndrome CRC patients.	C-EX-0618-01
Rish Pai	Mayo Clinic	Phase V Core CCFR Tumor IHC.	C-CP-0918-01
Rish Pai	Mayo Clinic	Clinicopathologic evaluation of small bowel carcinomas in patients with Lynch Syndrome	C-MA-1218-01
Rish Pai	Mayo Clinic	Development of a Digital Pathology Library for Development of Artificial Intelligence tools for Colorectal Carcinoma	C-MA-1218-02
Amanda Phipps	Fred Hutchinson Cancer Research Center	Descriptive Overview of CRC Phenotypes.	C-LA-0215-01-A1
Jamaica Robinson	Fred Hutchinson Cancer Research Center	Neighborhood influences on survival and health-related quality of life following a CRC diagnosis.	C-EX-0518-01
Uri Tabori	The Hospital for Sick Children	The effect of telomerase activity and telomere length on the biological behavior of cancer	C-EX-1218-02

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
--2017--			
Jeff Bacher	Promega Corp	Validation of a new biomarker panel for detection of MSI in colon cancers.	C-EX-0817-01
Jeff Bacher	Promega Corp	Validation of a new biomarker panel for detection of MSI in extra-colonic cancers.	C-EX-0817-02
Josee Dupuis	Boston University School of Medicine	Novel statistical methods for multi SNPs/multi DNA methylation probes association study using the OFCCR.	C-EX-0717-01
Sheetal Hardikar	Fred Hutchinson Cancer Research Center	Association between methylation patterns and cancer outcomes in unaffected relatives within Lynch families.	C-EX-0917-01
Polly Newcomb	Fred Hutchinson Cancer Research Center	Demographic and cancer-specific characteristics and outcomes of persons who deny a recent cancer diagnosis.	C-SE-0117-01
Constantinos Parisinos	University College London	The role of hepatic metabolites, metabolic pathways and function in CRC.	C-EX-0117-02
Oscar Puig	Phosphorous, Inc.	The discovery of novel genes and biomarkers of colon cancer using whole genome sequencing and determination of genetic penetrance.	C-EX-0517-01
Amanda Sheppard	Cancer Care Ontario; Univ of Toronto	Factors associated with CRC risk among self-identified First Nations participants in the OFCCR.	C-EX-0417-01
Steven Thibodeau	Mayo Clinic	Phase IV Core CCFR gMMR testing.	C-CP-1217-01
--2016--			
Irene Andrulic	Lunenfeld-Tanenbaum Research Institute	Collaboration with OFBCR on the BRIDGES Project.	C-EX-0416-01
Nicholas Chia	Mayo Clinic	Simulation of Conditions Leading to Colon Cancer using Host-Microbiome Metabolic Modeling.	C-EX-0316-02
Peter Crouch	Univeristy of Melbourne	Laser Ablation Inductively Coupled Plasma Mass Spectrometry imaging of CRCs.	C-EX-0416-02
Steve Gallinger	Mount Sinai Hospital, University of Toronto	Characterization of CRC immune landscape.	C-CP-1216-01
Michael Hall	Fox Chase Cancer Center	Sarcoma: a Lynch syndrome associated malignancy?	C-EX-0316-01
Richard Hayes	New York University Medical Center	Genes, Environment and CRC in People <50 Years of age.	C-EX-0516-01
Fred Hollande	University of Melbourne	Role of the tight junction protein claudin-2 in the regulation of CRC stem cells – consequences on post-treatment relapse and patient survival.	C-EX-0516-03
Scott Kopetz	MD Anderson Cancer Center, University of Texas	CRC risk and survival by consensus molecular subtype.	C-EX-1116-01
Noralane Lindor	Mayo Clinic	CCFR RNA QC Pilot, CORE project.	C-CP-0616-01
Josine Min	University of Bristol	Systematic identification of methylation quantitative loci and the link between methylation and complex traits.	C-EX-0816-01
Pal Moller	Oslo University Hospital	Prospective Lynch Syndrome Database Contribution.	C-EX-0716-01
Amanda Phipps	Fred Hutchinson Cancer Research Center	Bacterial correlates of CRC subgroups and survival.	C-SE-0816-01
Steven Thibodeau	Mayo Clinic	Phase IV Core CCFR IHC Testing.	C-CP-0916-01
Jeff Wrana	Lunenfeld-Tanenbaum Research Institute	qTAP, A Novel Platform for Personalized Medicine in Cancer, a Study in Collaboration with Sinai Health System's Ontario Familial CRC Registry	C-EX-0416-03

--2015--

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
John Baron	University of North Carolina at Chapel Hill	Descriptive Overview of CRC Phenotypes.	C-LA-0215-01
James Church	The Cleveland Clinic Foundation	Genetic Pathways of Interval CRC.	C-LA-0915-01
Stacey Cohen	Fred Hutchinson Cancer Research Center	Comparison of similarities and differences in tumor pathologic and molecular features between cases and their first-degree relatives with CRC.	C-EX-0415-01
Justin Guinney	Sage Bionetworks	Integration of biomarkers with AJCC staging in colon cancer.	C-EX-0115-01
Robert Haile	Stanford University	Hypomethylation-induced over-expression of oncogenes in cancer.	C-ST-0515-01
Robert Haile	Stanford University	The Breast and Colon Cancer Resilience Project.	C-ST-0515-02
Sheetal Hardikar	Fred Hutchinson Cancer Research Center	Leukocyte telomere length differences and survival after CRC diagnosis.	C-EX-0115-05
Sheetal Hardikar	Fred Hutchinson Cancer Research Center	Leukocyte telomere length differences and survival after CRC diagnosis.	C-EX-0115-05-A1
John Hays	The Ohio State University Wexner Medical Center	The role of mucinous histology in the association between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and mortality from CRC.	C-EX-0815-04
Mark Jenkins	University of Melbourne	Mechanisms for varying CRC risk (penetrance) for Lynch syndrome.	C-AU-0815-02
Maija Kohonen-Corish	Garvan Institute of Medical Research	Investigation of Elevated Microsatellite Alterations at Selected Tetranucleotide (EMAST) repeats in Lynch Syndrome-associated CRC	C-EX-0815-03
A. Joan Levine	Stanford University	Screening Practices in Type X CRC Families.	C-EX-0815-01
Joan Levine	Stanford University	The role of Fusobacterium nucleatum in CIMP tumorigenesis.	C-EX-1215-02
Georg Luebeck	Fred Hutchinson Cancer Research Center	Multiscale Study of Tissue Aging, Field Cancerization, and Colorectal Screening.	C-EX-0515-01
Finlay Macrae	InSiGHT (Internat'l Society of Dept: Gastrointestinal Hereditary Tumours)	Submission of the germ line variants of mismatch repair genes detected by the Colon CFR to the InSiGHT Variant Interpretation Committee and relevant databases.	C-AU-0815-01
Santos Manes	Centro Nacional de Biotecnologia	Identification of novel therapeutic targets for the treatment of cancer by means of genome-wide association studies (GWAS) and biological.	C-EX-0315-01
Polly Newcomb	Fred Hutchinson Cancer Research Center	International Survival Analysis in CRC Consortium (ISACC).	C-SE-0815-01
Polly Newcomb	Fred Hutchinson Cancer Research Center	Serrated CRC: An Emerging Disease Subtype.	C-SE-0415-01
Maartje Nielsen	Leiden University Medical Centre	Defining the non-colonic, non-endometrial cancer risks associated with a mono-allelic germline PMS2 mutation.	C-EX-0615-01
Albert Ostrer	Albert Einstein College of Medicine	Predicting Colon Cancer Risk from Functional Variant Assays.	C-EX-0815-02
Albert Tenesa	University of Edinburgh	CRC risk predictions from genome-wide SNP data and environmental risk factors.	C-EX-0315-02
Ursula Tsosie	Fred Hutchinson Cancer Research Center	Changes in multivitamin use after diagnosis of CRC.	C-EX-0115-03
Aung Ko Win	University of Melbourne	Metabolic Factors, medical conditions, and CRC Risk.	C-EX-0215-01
Zhengdong Zhang	Nanjing Medical University	Understanding the genetic effects on CRC risk.	C-EX-0115-02
--2014--			
Driss Ait Ouakrim	University of Melbourne	Social determinants of CRC screening, treatment and outcomes in the Colon-CFR.	C-EX-0914-01

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
D. Timothy Bishop	Institute of Genetic Medicine	Pharmacogenetic influences on colorectal chemoprevention using aspirin.	C-EX-1213-01-A1
Daniel Buchanan	University of Melbourne	Multiple and Integrative Approaches to Unravelling the Aetiology of FCCTX.	C-AU-1014-02
Daniel Buchanan	University of Melbourne	Phase IV KRAS_BRAF somatic mutation in CRCs from C-CFR.	C-CP-0814-01
Daniel Buchanan	University of Melbourne	Somatic mutations and additional molecular characterization of individuals with suspected Lynch syndrome.	C-AU-1014-01
Stacey Cohen	Fred Hutchinson Cancer Research Center	Evaluation of the impact of aspirin/NSAID therapy on the development of cancer in Familial CRC Type X families.	C-EX-0914-02
David Conti	University of Southern California	A Bayesian Hierarchical Quantile Regression Model to Prioritize GWAS Results.	C-EX-0314-01
Steve Gallinger	Lunenfeld-Tanenbaum Research Institute	Molecular Characterization of Familial CRC Type X.	C-TO-1014-01
Mark Jenkins	University of Melbourne	Genetics and Epigenetics of incident CRCs from the C-CFR.	C-AU-0814-01
Noralane Lindor	Mayo Clinic	Following Up Leads from the CCFR Custom Capture Sequencing.	C-MA-0814-01
Noralane Lindor	Mayo Clinic	PMS2-related Lynch Syndrome: Consideration of cancer screening recommendations.	C-MA-0614-01
Georg Luebeck	Fred Hutchinson Cancer Research Center	Tissue Aging and Tumor Heterogeneity in CRC: A Multiscale Approach.	C-EX-0514-01
Paul Marjoram	University of Southern California	Exploration of somatic mutations rates in Colon CCFR samples.	C-EX-0514-02
Elena Martinez	UC San Diego	Clinical Strategies for Identifying Individuals at Risk for Young Onset CRC: A Colon CFR-based Study.	C-EX-1114-01
Maartje Nielsen	Leiden University Medical Centre	Cancer risk in family members of CMMR-D patients.	C-EX-0314-02
Mala Pande	University of Texas, MD Anderson Cancer Center	Effect of Physical Activity on CRC Risk in MMR-Mutation Carriers and their MMR-intact Relatives.	C-EX-0314-03
Amanda Phipps	Fred Hutchinson Cancer Research Center	POLE Mutations in CRC: Identification and characterization of an emerging driver in CRC development.	C-EX-0614-02
Leonid Raskin	Vanderbilt	Targeted sequencing of CRC cases and controls.	C-EX-0814-01
Bryony Thompson	QIMR Berghofer Medical Research Institute	Evaluation of Mismatch Repair Gene Unclassified Sequence Variants.	C-EX-0806-02-A1
Zhe Wang	Fred Hutchinson Cancer Research Center	Red Meat Consumption and CRC Incidence and Mortality in Seattle CCFR Study.	C-EX-0214-01
Aung Ko Win	University of Melbourne	Clinical Outcomes after Colorectal Surgery.	C-AU-1110-01-A1
Aung Ko Win	University of Melbourne	Risk factors for CRC by molecular subtypes.	C-EX-0514-03
--2013--			
Jeff Bacher	Promega Corp	Validation of a novel MSI panel.	C-EX-1013-03
John Baron	University of North Carolina at Chapel Hill	Exogenous Estrogens, Reproductive History and CRC.	C-LA-0213-01
Bernard Bochner	Memorial Sloan Kettering Cancer Center	Genetic Sequencing of Urothelial Cancers in Patients with Lynch Syndrome.	C-EX-1113-01
Daniel Buchanan	University of Melbourne	Clinicopathological, molecular and epigenetic features of CRCs that are predictive of germline MUTYH gene mutations.	C-AU-1013-02
Daniel Buchanan	University of Melbourne	Clinicopathological, molecular and epigenetic features of sebaceous lesions from MMR gene mutation carriers.	C-AU-1013-01

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
John Burn	Institute of Genetic Medicine	Pharmacogenetic influences on colorectal chemoprevention using aspirin.	C-EX-1213-01
Graham Casey	Keck School of Medicine, University of Southern California	Genotyping of Colon CFR DNA samples using the OncoArray.	C-CP-0713-01
Sean Cleary	University of Toronto	Genetic variants associated with CRC survival: validation of HIF2A and HIF2B variants in OFCCR.	C-EX-0513-01
Carolyn Compton	Arizona State University	Critical Decision-making Support Tool for Colon Cancer Patients and their Caregivers.	C-EX-0713-01
Victoria Cortessis	University of Southern California	Genome-wide Association Analysis of Testicular Germ Cell Tumors.	C-EX-0613-01
Chu Gan	Royal Melbourne Hospital	Validation of MMR prediction models in the Chinese populations.	C-EX-0813-01
S Kupfer, G Rodrigo	The University of Chicago	Cancer risks and mutation spectrum of mismatch repair gene mutations in African American families with Lynch syndrome.	C-EX-0613-02
Diether Lambrechts	VIB	Novel MSI Marker Panel and de Novo Mutations in MMR Gene Mutation Carriers.	C-EX-1013-02
Noralane Lindor	Mayo Clinic	Expanded Characterization of Familial CRC Type X.	C-CP-0307-01-A1
Georg Luebeck	Fred Hutchinson Cancer Research Center	Biological modeling and risk prediction for CRC.	C-SE-0113-01
Ulrike Peters	Fred Hutchinson Cancer Research Center	Molecular pathological epidemiology of CRC.	C-EX-0913-01
Amanda Phipps	Fred Hutchinson Cancer Research Center	Racial/ethnic differences in the prevalence of PIK3CA mutations in CRC.	C-EX-0913-02
Douglas Stupart	Deakin University	Fecundity bias in detecting genetic anticipation in Lynch syndrome.	C-EX-0513-02
Albert Tenesa	University of Edinburgh	Estimation of aggregate pleiotropy between BMI, colon and rectal cancer using CFR population-based and clinic-based cases, controls and families.	C-EX-0113-01
Fränzel van Duijnhoven	Wageningen University	Collaborative Study on the Role of Lifestyle Factors/Diet/Body Fatness Development of Tumors in Lynch Syndrome.	C-EX-1213-02
Aung Ko Win	University of Melbourne	Childhood Cancers in Families with and without Mismatch Repair Gene Mutations.	C-EX-1013-01
--2012--			
Dennis Ahnen	University of Colorado School of Medicine	Molecular Identification of Lynch Syndrome.	C-LA-0711-01
Rajani Bharati	University of Melbourne	Family History of CRC as a risk factor for Endometrial Cancer.	C-EX-0412-02
Jason Bielas	Fred Hutchinson Cancer Research Center	Novel Biomarkers of Disease.	C-EX-0613-03
Laurent Briollais	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	Development of Multistate Models for Screening Evaluation and Risk Estimation in Lynch Syndrome Families.	C-EX-0212-01
Daniel Buchanan	University of Melbourne	Young Onset CRC: Genetics, Pathology And Environment.	C-AU-0312-01
Rowena Chau	University of Melbourne	Profiling risk of familial CRCs using data mining.	C-EX-0412-01
Steve Gallinger	Mount Sinai Hospital, University of Toronto	HOXB13 G84E mutation in a CRC population.	C-TO-0512-01
Anthony Gill	Royal North Shore Hospital	Investigation of mutation specific immunohistochemistry for BRAFV600E to distinguish Lynch syndrome from somatic hypermethylation as a cause of negative staining	C-EX-0212-02
Stacey Hart	Ryerson University	Long-term Physical and Psychological Outcomes in CRC Survivors.	C-EX-1111-05

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
Joanne Kim	University of Toronto	Investigating the effectiveness of predictive genetic testing for CRC in modifying lifestyles and improving health.	C-EX-0911-03
Mercy Laurino	Fred Hutchinson Cancer Research Center	The Return of Research Results in the CRC Family Registry.	C-EX-0412-04
Ariadne Letra	University of Texas Health Science Center	Identification of genetic pathways linking tooth agenesis to CRC.	C-EX-1111-03
Noralane Lindor	Mayo Clinic	Protein Microarray Signature of Autoantibody Biomarker for Detection of CRC.	C-MA-0412-01
Duncan Thomas	University of Southern California	Study design for next generation sequencing.	C-LA-0412-01
Aung Ko Win	University of Melbourne	Studying tumor pathology features of CRC cases.	C-EX-1111-02
Y. Nancy You	MD Anderson Cancer Center, University of Texas	Young-onset microsatellite stable CRC.	C-EX-0212-03
--2011--			
David Conti/Schumacher	University of Southern California	Incorporating intermediate biomarkers in a pathway-based model of folate and colon cancer.	C-EX-1211-01
Mark Jenkins	University of Melbourne	Development of a Comprehensive Model for CRC Risk Predication.	C-AU-1210-01
A. Joan Levine	University of Southern California	Risk of Colorectal or Other Cancers in MLH1 Methylated Cases.	C-CP-0111-01
Noralane Lindor	Mayo Clinic	Efficacy of Treatment of Colon Cancer with Fluorouracil Treatment in Hereditary DNA Mismatch Repair Deficiency Syndrome (Lynch Syndrome).	C-MA-1110-01
Noralane Lindor	Mayo Clinic	Urologic tumors in Lynch Syndrome and Familial CRC Type X.	C-MA-0311-02
Paul Marjoram	University of Southern California	Assessing Optimal Follow-up to Associations from GWAS.	C-EX-0111-02
Polly Newcomb	Fred Hutchinson Cancer Research Center	Predictors of CRC Screening in Relatives of CRC Patients.	C-SE-0504-01S-A1
Susan Parry	Middlemore Hospital & Auckland City Hospital	Clinical Outcomes after Colorectal Surgery.	C-AU-1110-01
Ian Tomlinson	University of Oxford	Use of CCFR controls to improve the power of other cancer GWAS.	C-EX-0411-01
Aung Ko Win	University of Melbourne	Germline <i>de novo</i> mutations in DNA mismatch repair genes.	C-EX-0111-01
Aung Ko Win	University of Melbourne	Risk factors of early-onset CRC.	C-EX-1010-01
--2010--			
Scott Adams	Fred Hutchinson Cancer Research Center	Impact of Inflammatory Bowel Disease on CRC Mortality.	C-EX-1209-01
Driss Ait Ouakrim	University of Melbourne	CRC Screening in Australia.	C-EX-1008-01
Lisa Boardman	Mayo Foundation	Are Germline PKHD1 Mutations Protective Against CRC?	C-EX-0410-01
Daniel Buchanan	University of Melbourne	Genetic Modifiers of MUTYH-associated Polyposis.	C-AU-0410-01
George A Calin	MD Anderson Cancer Center, University of Texas	Identification of Non-Coding RNAs Involved in CRC Predisposition.	C-EX-0509-01
Peter Campbell	American Cancer Society	Obesity-related Genes FTO and MC4R and Risk of CRC.	C-EX-0710-04
Louisa Flander	University of Melbourne	Personal CRC risk, gene testing and prevention behaviour in mutation-carrying families.	C-EX-0309-02
Brooke Fridley	Mayo Clinic	Analysis of 8q24 for seven cancers for association reveals common locus for cancer risk.	C-EX-0810-01
Stephen Gruber	Norris Comprehensive Cancer Center, University of Southern California	Transdisciplinary Studies of Genetic Variation in CRC (CORECT).	C-EX-1110-02

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
A. Joan Levine	University of Southern California	Dietary Supplements and CRC Risk in the Colon Cancer Family Registry.	C-EX-0410-02
Noralane Lindor	Mayo Clinic	Admin Supplement for the Familial Colorectal Neoplasia Collaborative Group U01CA074800.	C-CP-0910-01
Noralane Lindor	Mayo Clinic	IHC for DNA Mismatch Repair Genes in Prostate Cancers arising in Men with MMR Gene Mutations.	C-MA-1010-01
Noralane Lindor	Mayo Clinic	Oligodontia in CRC.	C-MA-1109-01
Xaviar Llor	Yale University School of Medicine	Ascertainment of Genes Responsible for HNPCC without Mismatch Repair Deficiency.	C-EX-0610-01
Polly Newcomb	Fred Hutchinson Cancer Research Center	Common Medications and Risk of CRC.	C-SE-0510-01
Katy Newton	Central Manchester University Hospitals Trust	DNA Mismatch Gene Promoter Region Methylation Analysis and BRAF Gene Mutation Analysis-an Alternative Prescreening Strategy in LS.	C-EX-0710-01
Mala Pande	University of Texas, MD Anderson Cancer Center	Identification of novel susceptibility markers associated with the breast-colon family phenotype from Genome-Wide Scan data.	C-EX-1209-02
Susan Parry	Middlemore Hospital & Auckland City Hospital	Clinical Outcomes for MMR Gene Mutation Carriers Following CRC Surgery.	C-AU-1109-01
William Pollett	Memorial University of Newfoundland	Adherence to Clinical Practice Guidelines for Adjuvant Therapy in Patients with Stage I-III Rectal Cancer: Experience in Two Canadian Provinces.	C-EX-0805-07-A1
Stephen Scherer	Hospital for Sick Children	International Psychiatric Genetics Consortium.	C-EX-0910-01
Duncan Thomas	University of Southern California	Methods of Pathway Analysis with Application to Folate.	C-LA-0910-01
Michael Walsh	Queensland Institute of Medical Research	Diagnostic usefulness of adenomas in Lynch Syndrome.	C-EX-1009-02
Aung Ko Win	University of Melbourne	Environmental Modifiers of Endometrial Cancer Risks among Carriers of Germline Mutations in DNA MMR Gene.	C-EX-0410-03
Aung Ko Win	University of Melbourne	Use of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and CRC Risk for Carriers of Germline Mutations in DNA Mismatch Repair Gene.	C-EX-0710-03
Shuanglin Zhang	Michigan Technological University	Statistical Models for Family-based Association Studies.	C-EX-0210-02
--2009--			
Daniel Buchanan	University of Melbourne	A Case-Control Genome-Wide Association Study to Identify the Locus Responsible for Hyperplastic Polyposis Syndrome.	C-AU-0808-01
Daniel Buchanan	University of Melbourne	BRAF V600E somatic mutation in CRC - Phase I, II and II Proband.	C-CP-0309-02
Daniel Buchanan	University of Melbourne	Testing for Germline mutations in PMS2 in the Colon-CFR - Phase II and III Proband.	C-CP-0309-01
Antoni Castells	University of Barcelona, Spain	Identification of Mismatch Repair Gene Carriers in Patients with CRC: A Pooled Data Analysis.	C-EX-0509-04
Rachel Ceballos	Fred Hutchinson Cancer Research Center	Quality of Life in the Seattle C-CFR.	C-EX-0808-06
Sean Cleary	University of Toronto	The association of cigarette smoking and genetic polymorphisms in carcinogen metabolizing enzymes with pancreatic cancer risk.	C-EX-0109-01
Malcolm Dunlop	MRC Human genetics Unit Western General Hospital Edinburgh	Genetic profiling of CRC risk.	C-EX-0109-02
Malcolm Dunlop	MRC Human genetics Unit Western General Hospital Edinburgh	Pooled analysis of colon-CFR genome-wide association data.	C-EX-0509-02

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
William Foulkes	Sir Mortimer B. Davis Jewish General Hospital	Allelic expression of spindle assembly checkpoint genes in CRC.	C-EX-0309-01
Lyle Gurrin	University of Melbourne	SNPs of iron metabolism and risk CRC.	C-EX-0409-01
Mark Jenkins	University of Melbourne	Anthropometry and CRC Risk in Mismatch Repair Gene Mutation Carriers.	C-AU-0909-01
Mark Jenkins	University of Melbourne	Genetic modifiers of cancer risk for mismatch repair mutation carriers: SNPs from genome wide association studies.	C-AU-0409-01
Loic Le Marchand	Cancer Research Center of Hawaii, University of Hawaii at Manoa	CRC GWAS in Japanese and African Americans.	C-HA-0309-01
Noralane Lindor	Mayo Clinic	Methylation of the MMR Genes in Individuals with Loss of Expression of MSH2 in CRC but No Mutation Detected.	C-AC-0109-01
Roger Milne	Spanish National Cancer Research Centre	Variation in genes related to inflammation and tumor progression and risk of pancreatic cancer.	C-EX-0409-02
Polly Newcomb	Fred Hutchinson Cancer Research Center	Factors Associated with Survival After CRC.	C-SE-0109-02
Polly Newcomb	Fred Hutchinson Cancer Research Center	NSAID Use and CRC Survival in a CFR Population.	C-SE-0109-01
Ulrike Peters	Fred Hutchinson Cancer Research Center	CRC GWAS Consortium (GECCO).	C-EX-0509-03
Steven Thibodeau	Mayo Clinic	Ph II & III DNA mutation analysis for MLH1/MSH2/MSH6 and Custom Capture.	C-CP-0409-01
Cornelia Ulrich	Huntsman Cancer Institute	NSAID Metabolism, Cox/PG Pathway and CRC.	C-SE-1203-01-A1
--2008--			
Haitao Chu	UNC-Chapel Hill	Diagnosis and risk factors of microsatellite instability.	C-EX-1107-01
Timothy Church	University of Minnesota School of Public Health	CRC Family History Screening Validation Project.	C-LA-0408-01
Jeremy Fields	CA*TX	Screening for CRC (CRC) / Hereditary Non-Polyposis Colorectal Cancer (HNPCC).	C-EX-0808-04
Steve Gallinger	Mount Sinai Hospital, University of Toronto	PanScan II.	C-TO-0408-01
John Hopper	University of Melbourne	Candidate gene study using Colon CFR population-based and clinic-based cases, controls and families.	C-AU-0808-02
Mark Jenkins	University of Melbourne	Cancer Risk for Germline Mutations in hPMS2.	C-AU-1007-01
Mark Jenkins	University of Melbourne	Modeling environmental and genetic modifiers of mismatch repair gene mutations using family data.	C-AU-0208-01
Loic Le Marchand	Cancer Research Center of Hawaii, University of Hawaii at Manoa	Genome-Wide Association of Gene Variation and Expression in CRC.	C-HA-1207-01
A. Joan Levine	University of Southern California	Global DNA Hypomethylation in PBLs as a potential biomarker of CRC Risk.	C-EX-1207-01
Polly Newcomb	Fred Hutchinson Cancer Research Center	Human papillomavirus association with subsets of CRC.	C-SE-0408-01
Boris Pasche	University of Alabama at Birmingham	The role of the adiponectin, leptin and insulin pathway in colon cancer.	C-EX-0808-03
--2007--			
Yoland Antill	Peter MacCallum Cancer Centre	Studies into Gynecological Cancers Associated with the Syndrome: Hereditary Nonpolyposis Colon Cancer.	C-EX-0706-02
Bharati Bapat	Mount Sinai Hospital, University of Toronto	Epigenetic Contribution of Wnt Pathway Regulatory Genes to CRC.	C-TO-1206-01
Lisa Boardman	Mayo Foundation	Genetic Epidemiology of Telomere Length and Telomere Maintenance Genes.	C-EX-0407-01

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
Graham Casey	Keck School of Medicine, University of Southern California	Identification of Gene Expression Patterns Related to Genetic Subclasses of CRCs using the Affymetrix Whole Exon Gene Expression Array (CORE Activity).	C-CP-0107-01
Carolyn Gotay	Cancer Research Center of Hawaii, University of Hawaii at Manoa	An Online Exercise Program for Individuals At Risk of CRC: A Pilot Study.	C-HA-0806-02
Garry Hannan	CSIRO Molecular & Health Technologies	Genome Wide Association Study to Identify Novel Genetic Modifiers of the Hereditary Non-polyposis CRC (HNPCC) Gene, HMLH1.	C-EX-1206-03
Garry Hannan	CSIRO Molecular & Health Technologies	Novel CRC Genes: High Throughput Screening for Genetic Analysis of CRC Risk.	C-EX-1206-02
Hormuzd A. Katki	National Cancer Institute	Extending MMRpro to Handle Misreported Family History.	C-EX-1106-01
Wendy Kohlmann	Huntsman Cancer Institute	The Effect of Smoking on Urothelial Cancer Risk in Individuals with HNPCC.	C-EX-0906-01
Loic Le Marchand	Cancer Research Center of Hawaii, University of Hawaii at Manoa	8q24 and CRC in the CCFR.	C-CP-0407-01
Loic Le Marchand	Cancer Research Center of Hawaii, University of Hawaii at Manoa	Inflammation and Innate Immunity Genes and CRC.	C-HA-0806-01
Paul Limburg	Mayo Clinic	Expanded Characterization of Familial CRC Type X.	C-CP-0307-01
Noralane Lindor	Mayo Clinic	Development of a Family-Based Cancer Prevention Intervention for Cancer Survivors who are Family Members.	C-MA-0407-01
Gail McKeown-Eyssen	University of Toronto	Familial Clustering Of Environmental And Genetic Risk Factors: Extension of Analytic Methods.	C-AC-0707-01
Andreas Obermair	Queensland Centre for Gynaecological Cancer, Royal Brisbane & Women's Hospital	Incidence of Endometrial Cancer in Lynch Syndromes after a Diagnosis of CRC.	C-EX-0706-01
Mala Pande	University of Texas, MD Anderson Cancer Center	Smoking as a modifier of risk of CRC in Lynch syndrome.	C-EX-0307-01
Harry Prapavessis	The University of Western Ontario	Initiating and Maintaining Exercise in Relatives of CRC: A Test of Self-Regulation Theory.	C-EX-0407-03
Michael Reedijk	Mt Sinai Hospital, University Health Network	Activation of Notch Signaling in Human Colon Cancer, Clinicopathologic Correlations.	C-EX-0806-04-A1
Betsy Risendal	University of Colorado and Denver Health Sciences Center	Quality of Life and Health-Related Behaviors among Long-Term Colon Cancer Survivors.	C-EX-0407-02
Ben Roa	Myriad Genetics Laboratories, Inc.	Mismatch Repair Gene Mutations in Early CRC.	C-EX-0804-02
Mark Silverberg	University of Toronto, Mount Sinai Hospital	Genetic Predictors of Gastrointestinal Cancer in Patients with Inflammatory Bowel Disease.	C-EX-1206-04
Sapna Syngal	Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School	External Validation and Comparison of PREMM Model with Current Predictive Models for Lynch Syndrome.	C-EX-1006-01
Sapna Syngal	Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School	The Prevalence of p53 Germline Mutations in Very Young-Onset CRC.	C-EX-1206-05
Csilla Szabo	Mayo Clinic	Candidate Gene Screening in Familial Breast-Colon Cancer.	C-EX-1206-01
Jensen Tan	University of Toronto	Processes of Care after CRC Surgery in Ontario.	C-EX-1007-01
Ian Tomlinson	Cancer Research, United Kingdom	Validation or Rejection of Genetic Variants with Suggestive Association with Increased Risk of CRC.	C-EX-0807-01
Michael Woods	Memorial University of Newfoundland	Genetic Anticipation and Parent-of-Origin Effects in Families with Mismatch Repair Defects.	C-EX-0107-01
Brent Zanke	Cancer Care Ontario; Univ of Toronto	Cancer Risk Evaluation (CaRE) Program.	C-EX-0807-02

--2006--

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
Daniel Buchanan	University of Melbourne	BAT26 Stability in MMR Deficient Tumours as an Indication of Large Deletions in Exon 5 of MSH2.	C-AU-0506-01
Daniel Buchanan	University of Melbourne	Genetics of Serrated Neoplasia.	C-AU-0506-02
Daniel Buchanan	University of Melbourne	Pilot Study of BRAF Mutation Levels in Clinic-Based CRC Families.	C-AU-0406-02
Daniel Buchanan	University of Melbourne	Pilot Study of LCL Expression Arrays in Hyperplastic Polyposis.	C-AU-0406-01
Daniel Buchanan	University of Melbourne	Preliminary Linkage Analysis of Serrated Pathway Families.	C-AU-0805-05
Daniel Buchanan	University of Melbourne	The Molecular Characterization of Endometrial Tumours.	C-AU-0406-03
Graham Casey	Keck School of Medicine, University of Southern California	Genomic Wide Association Study of CRC.	C-LA-0806-01
Albert de la Chapelle	Ohio State University	Characterization of Mutations in the PMS2 Gene in Samples from the Colon Cancer Family Registry.	C-EX-0806-01
Mary Jane Esplen	Toronto General Research Institute, University Health Network	A Pilot Study Investigating the Offer to Disclose Genetic Test Results to CFR Participants.	C-EX-0806-05
Anna Gagliardi	Sunnybrook Health Sciences Centre, Toronto	Exploring the Cognitive Processes that Influence Intra-Operative Decisions during CRC Surgery: Qualitative Analysis of Operative Notes and Surgeon Interviews.	C-EX-0506-03
Carolyn Gotay	Cancer Research Center of Hawaii, University of Hawaii at Manoa	Communication about CRC in Japanese and Caucasian Survivors.	C-HA-0806-03
Virginia Hartmuller	National Cancer Institute	Proposal to Compare and Evaluate Responses to the Diet-Specific Questions on the Epidemiology Questionnaire in the Colon Cancer Family Registry (C-CFR).	C-CP-0206-01
Mark Jenkins	University of Melbourne	CRC Risk for Germline Mutations in hMLH1 and hMSH2.	C-CP-0606-03
A. Joan Levine	University of Southern California	Risk Factors for hMLH1 promoter region methylation in sporadic CRC.	C-CP-0506-03
Paul Limburg	Mayo Clinic	Associations between excess body weight and CRC risk, overall and by MSI phenotype.	C-CP-0506-02
Noralane Lindor	Mayo Clinic	Methylation of the MMR Genes in Individuals with Loss of Expression of MSH2 in CRC but No Mutation Detected.	C-CP-1206-01
Jan Lowery	University of Colorado	An Evaluation of the Association Between Physical Activity and MSI in Colon Cancer.	C-CP-0506-01
David Martin	Children's Hospital Oakland Research Institute	Somatic MLH1 Epimutation and Sporadic MSI Cancer Risk.	C-EX-0406-02
John McLaughlin	Prosserman Centre for Health Research, Mount Sinai Hospital	The Ontario Population Genomics Platform (OPGP).	C-TO-0406-01
Polly Newcomb	Fred Hutchinson Cancer Research Center	Combined Postmenopausal Hormone Use in Relation to Subtypes CRC defined by MSI/MMR/ Methylation Status.	C-CP-0806-01
Jenny Poynter	University of Southern California	Descriptive Characteristics and Familial Aggregation of MLH1 Promoter Methylation.	C-CP-0506-04
Jenny Poynter	University of Southern California	History for Predicting MMR Mutations.	C-CP-0506-06
Jenny Poynter	University of Southern California	Sensitivity, Specificity and Predictive Values for IHC, MSI and Family.	C-CP-0506-05
Pamela Sinicrope	Mayo Clinic	A Pilot Study to Compare General Attitudes toward Medical Significance Thresholds among Study Participants, Genetics Researchers, and Institutional Review Boards.	C-EX-0806-06
Amanda Spurdle	Queensland Institute of Medical Research	Evaluation of Mismatch Repair Gene Unclassified Sequence Variants.	C-EX-0806-02
Steven Thibodeau	Mayo Clinic	CRC Risk for Germline Mutations in hMSH6.	C-CP-0606-01

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
Steven Thibodeau	Mayo Clinic	MSH6 (lab manuscript).	C-CP-0606-02
Peter Wang	Memorial University of Newfoundland	Exploration of Risk Factors, Inter-provincial Differences and Risk Modifiers of CRC.	C-EX-0506-02
Robyn Ward	University of New South Wales	Germline Epimutation of MLH1 as a Factor in HNPCC.	C-EX-1205-01
Brian Ward	Myriad Genetics Laboratories, Inc.	Mismatch Repair Gene Mutations in Early CRC.	C-EX-0804-03
--2005--			
Carl Brown	University of Toronto	Survival in Patients with Inflammatory Bowel Disease Who Develop CRC.	C-TO-0405-02
Daniel Buchanan	University of Melbourne	Studies of Breast Cancers in HNPCC Kindreds.	C-AU-0805-04
Mary Jane Esplen	Toronto General Research Institute, University Health Network	A RCT of Cancer Risk and Health Education in Relatives of CRC Patients.	C-TO-0405-01-A1
Marsha Frazier	MD Anderson Cancer Center, University of Texas	Genetic Modifiers of Hereditary Nonpolyposis CRC.	C-EX-0405-02
Robert Gryfe	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	MSI-H CRC Genotype and Phenotype.	C-TO-0405-03
Jeremy Jass	McGill University	Evaluation of Histology Features as Markers for DNA Mismatch Repair Deficiency in CRC.	C-AU-0899-01
Noralane Lindor	Mayo Clinic	A Gene-Environment study of a-1 Antitrypsin Deficiency as a Risk Factor for Mismatch Repair Deficient CRC in Smokers and Non-Smokers.	C-MA-0805-01
Polly Newcomb	Fred Hutchinson Cancer Research Center	Predictors of Agreement to Provide a Blood or Buccal Biospecimen Sample.	C-SE-0305-01
Michael Siciliano	MD Anderson Cancer Center, University of Texas	MSI in Putatively Stable HNPCC Families.	C-EX-0405-01
Cornelia Ulrich	Huntsman Cancer Institute	Folate, Pharmacogenetics, and CRC Survival.	C-EX-0805-06
Debrah Wirtzfeld	Memorial University of Newfoundland	Prognostic Determinants in Incident Cases of CRC: A Comparison Between Ontario & Newfoundland Incident Cases of CRC 1999-2000.	C-EX-0805-07
--2004--			
Dennis Ahnen	University of Colorado School of Medicine	Colorectal Screening Practices in Members of High Risk Families.	C-LA-0804-02S
C. Richard Boland	Baylor University Medical Center	Using CFR Resources to Study HNPCC.	C-EX-1203-01
Deborah Bowen	Fred Hutchinson Cancer Research Center	Increasing Colon Screening with an Interactive Website.	C-SE-0404-01
Deborah Bowen	Fred Hutchinson Cancer Research Center	Predictors of CRC Screening in Relatives of CRC Patients.	C-SE-0504-01S
Manuela Gago-Dominguez	University of Southern California	A Genetic Epidemiological Study of Lipid Peroxidation in CRC.	C-LA-0404-01
Steve Gallinger	Mount Sinai Hospital, University of Toronto	The Base Excision Repair Gene, MYH, and CRC.	C-TO-1203-01
Robert Haile	University of Southern California	Genes Related to Folate and Vitamin D/Calcium.	C-LA-1203-01
Kelly Kohut	Sarah Lawrence College (Bronxville NY), Mt Sinai Hospital (Toronto ON)	Duty to Warn family about an HNPCC mutation.	C-TO-1299-01-C04
Nancy Kreiger	Cancer Care Ontario; Univ of Toronto	Prevalence of Helicobacter Pylori infection in Ontario.	C-TO-0404-01
Peter Laird	Van Andel Research Institution	CpG Island Methylator Phenotype in CRC.	C-LA-1203-02
Loic Le Marchand	Cancer Research Center of Hawaii, University of Hawaii at Manoa	Epidemiologic Research on Ethnic/Racial Minorities in the Colon CFR.	C-HA-1203-01
Sanford Markowitz	Case Western Reserve University	A 9q22.2 Gene is a Novel Cause of Familial Colon Cancer.	C-EX-1203-03
Elena Martinez	Arizona Cancer Center, University of Arizona	Susceptibility to Insulin Resistance Syndrome and Risk of CRC.	C-LA-0804-01

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
Gail McKeown-Eyssen	University of Toronto	Response Bias From Failure to Provide a Blood Sample Among Participants in the OFCCR.	C-TO-0304-01S
Walter W. Noll	Myriad Genetics Laboratories, Inc.	Mismatch Repair Gene Mutations in Early CRC.	C-EX-0804-01
Giovanni Parmigiani	Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Univ.	Validation of the CRCAPRO carrier probability model.	C-EX-0104-01
Brent Zanke	Cancer Care Ontario; Univ of Toronto	Assessment of Risk for Colon Tumors in Canada (ARCTIC).	C-EX-1203-02-A1
--2003--			
Bharati Bapat	Mount Sinai Hospital, University of Toronto	The Role of Polymorphisms in Mismatch Repair Genes in the Development of Colon Cancer.	C-TO-0503-01
Robert Beart	Keck School of Medicine, University of Southern California	Genetic Staging of Colon Cancer.	C-EX-0803-04-A1
D. Timothy Bishop	Cancer Research UK Clinical Centre, St. James's University Hospital	Quantifying and Modelling Cancer Risks in Relatives of Population-Based CRC Cases and Controls.	C-EX-0803-01
Michelle Cotterchio	Cancer Care Ontario; Univ of Toronto	The Effect of Access to an Interactive Colon Cancer Website on Subject Participation in the [OFCCR].	C-TO-0103-01S
Mazda Jenab	Cancer Care Ontario; Univ of Toronto	The association between dietary Vitamin D intake and CRC risk.	C-TO-0703-01S
Richard King	University of Minnesota School of Medicine	Proteomic and Genomic Analysis of CRC.	C-LA-1202-01
Peter Laird	University of Southern California	MLH1 promoter methylation.	C-CP-1103-02
Lisa Madlensky	University of California, San Diego	Health Behaviors and Family History of CRC.	C-EX-0803-03
Polly Newcomb	Fred Hutchinson Cancer Research Center	Effect Modification of Smoking by NSAIDs in CRC.	C-SE-0603-01S
John Potter	Fred Hutchinson Cancer Research Center	NSAID Metabolism, Cox/PG Pathway and CRC.	C-SE-1203-01
Maren Scheuner	Centers for Disease Control and Prevention	Clinical Validity Study of Colon Cancer Family History.	C-EX-0803-02-A1
Steven Thibodeau	Mayo Clinic	MLPA Study.	C-CP-1103-02
Cornelia Ulrich	Huntsman Cancer Institute	Pharmacogenetics of 5-Fluorouracil - Pilot.	C-SE-0803-01
Cornelia Ulrich	Huntsman Cancer Institute	Pharmacogenetics of Thymidylate Synthase Inhibitors.	C-SE-0803-02
--2002--			
Graham Casey	Keck School of Medicine, University of Southern California	Comparison of mutation detection platforms in patient samples with very high likelihood of carrying germline mutations in MLH1 or MSH2.	C-LA-0102-01S
Michelle Cotterchio	Cancer Care Ontario; Univ of Toronto	CRC Risk: Association with Epidemiologic Factors and Genetic Polymorphisms in Selected Enzymes That Activate Carcinogens and Metabolize Estrogens.	C-TO-1201-01
Noralane Lindor	Mayo Clinic	Risk of Cancers in Amsterdam I Families without MSI-H tumors: Are the cancer risks the same as in families with hereditary DNA mismatch repair defects?	C-MA-0902-01S
John McLaughlin	Prosserman Centre for Health Research, Mt Sinai Hospital	Estrogens and risk of CRC among women predisposed to hereditary nonpolyposis CRC (HNPCC).	C-TO-0202-01S
Robin McLeod	Mount Sinai Hospital, University of Toronto	Is obesity or overweight a barrier for CRC screening in average risk individuals residing in Ontario or Seattle?	C-TO-1101-01S
Polly Newcomb	Fred Hutchinson Cancer Research Center	JC Virus in CRC.	C-SE-0802-01
Boris Pasche	University of Alabama at Birmingham	Polymorphisms of the TGF- β Signaling Pathway and CRC Risk.	C-EX-1202-02
John Potter	Fred Hutchinson Cancer Research Center	Antibody (rScFv) Arrays for Colon Cancer Screening.	C-SE-0902-01S
Mariana Stern	University of Southern California	DNA repair and CRC risk within the USCC.	C-LA-0402-01

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
Steven Thibodeau	Mayo Clinic	Analysis of MSI-H colorectal tumors with normal hMLH1, hMSH2 and hMSH6 protein expression.	C-MA-0402-01
--2001--			
Dennis Ahnen	University of Colorado School of Medicine	Family History Characteristics in the Colon CFRs.	C-LA-0101-01
Dennis Ahnen	University of Colorado School of Medicine	Promoting Colon Cancer Screening Among Genetically Defined High-Risk Populations Within the Cooperative Family Registry for Colon Cancer Studies.	C-LA-0401-01
Lisa Boardman	Mayo Foundation	Family History of CRC (CRC) or Extracolonic Malignancies Among Young Onset CRC Patients.	C-MA-0201-02
Michelle Cotterchio	Cancer Care Ontario; Univ of Toronto	Association between Double Primary Endometrial-CRCs and Family History of Cancer, Subject Characteristics and Underlying Molecular Features.	C-TO-1100-01
Michelle Cotterchio	Cancer Care Ontario; Univ of Toronto	Family history of breast cancer and CRC risk in Ontario.	C-TO-0201-01S
Michelle Cotterchio	Cancer Care Ontario; Univ of Toronto	The efficacy of colorectal screening procedures in reducing CRC risk (incidence) among participants of a population-based case control study in Ontario.	C-TO-0101-01
Mary Jane Esplen	Toronto General Research Institute, University Health Network	The Development of an Instrument to Measure Self-Concept in HNPCC Gene Carriers.	C-TO-0401-01
Vivek Goel	University of Toronto	Screening in relatives of Ontario CRC patients.	C-EX-0401-02-A1
Noralane Lindor	Mayo Clinic	Loss of expression of MLH1 as a function of aging.	C-MA-0501-01
Noralane Lindor	Mayo Clinic	Microsatellite Instability Test Results: Perspectives from Patients.	C-MA-0801-01
Noralane Lindor	Mayo Clinic	Microsatellite Instability Testing versus Immunohistochemistry for Phenotyping of Colorectal Tumors.	C-MA-0201-01
Noralane Lindor	Mayo Clinic	Parent of Origin Effects in CRC Predisposition.	C-MA-0401-02
Noralane Lindor	Mayo Clinic	Prevalence of the APC E1317Q variant in patients with multiple adenomatous polyps and CRC patients.	C-MA-0401-01
Sheila Murphy	University of Southern California	Understanding Uncertainty: Communicating the Genetic Risk of Cancer.	C-EX-0401-03
Polly Newcomb	Fred Hutchinson Cancer Research Center	Genotype-phenotype correlation of IGF-1.	C-SE-0401-01
Gloria Peterson	Mayo Clinic	Accuracy of family history of cancer provided by CRC patients.	C-MA-0301-01
Scott Ramsey	Fred Hutchinson Cancer Research Center	Preferences for Genetic Testing for HNPCC: A comparison of colon cancer patients, their immediate family members, and the general population.	C-SE-0801-01
Andrew Smith	Sunnybrook Health Sciences Centre, Toronto	Quality improvement in lymph node assessment for CRC.	C-TO-1201-01S
Steven Thibodeau	Mayo Clinic	Mechanisms of MSH6 inactivation in mismatch repair deficient tumors.	C-MA-0401-03
--2000--			
Deborah Bowen	Fred Hutchinson Cancer Research Center	The Needs of Families with CRC.	C-SE-1200-01-A1
Michelle Cotterchio	Cancer Care Ontario; Univ of Toronto	Agreement between proxy- and case-reported information obtained using the self-administered OFCCR epidemiologic questionnaire.	C-TO-0000-01
Ellen Goode	Mayo Clinic	Identification of Novel Cancer Susceptibility Loci: A Sib-Pair Study.	C-SE-0000-01CS
Robert Haile	University of Southern California	A Molecular Epidemiology Study of Loss of Imprinting.	C-LA-0800-01
Polly Newcomb	Fred Hutchinson Cancer Research Center	Efficacy of Screening Tests to Prevent CRC.	C-SE-0800-01S

COLON CANCER FAMILY REGISTRY (CFR) APPROVED APPLICATIONS FOR COLLABORATION

Principal Investigator	PI Institution	Title	App ID
Polly Newcomb	Fred Hutchinson Cancer Research Center	Modeling Risk for CRC- Projecting Individualized Probabilities.	C-SE-0400-01S
John Potter	Fred Hutchinson Cancer Research Center	DNA Damage Repair.	C-SE-0400-01
Scott Ramsey	Fred Hutchinson Cancer Research Center	A multifactorial economic model of risk stratification and screening for colon cancer.	C-SE-0800-02S
H. Zarbl	Fred Hutchinson Cancer Research Center	A Pilot Study to Test the Validity of Constant Denaturing Capillary Electrophoresis for Mutation Detection of MMR Genes in CRC.	C-SE-0400-02AS
--1999--			
Bharati Bapat	Mount Sinai Hospital, University of Toronto	Investigation of tumor MSI status versus family history characteristics among CRC patients.	C-MA-0499-02-E03
Bharati Bapat	Mount Sinai Hospital, University of Toronto	The Role of Susceptibility Genes and Environmental Risk Factors in the Etiology of Mutator versus Suppressor Pathway of CRC.	C-TO-0899-02
Michelle Cotterchio	Cancer Care Ontario; Univ of Toronto	The Cumulative Risk of Colon and Endometrial Cancer among HNPCC Susceptibility Gene Mutation Carriers in Ontario.	C-TO-0899-03
Alexandria Easson	Princess Margaret Hospital	The surgical management of potentially curable colon cancer in Ontario.	C-TO-0899-04
Mary Jane Esplen	Toronto General Research Institute, University Health Network	Development of a Group Intervention for HNPCC Gene Carriers.	C-TO-0899-01
Mary Jane Esplen	Toronto General Research Institute, University of Toronto	Psychosocial & Behavioral Impact of Predictive DNA Testing for Hereditary Nonpolyposis CRC.	C-TO-1299-01
Jeremy Jass	University of Queensland	Genetic Screening for HNPCC in High Risk Families.	C-AU-0506-02
A. Joan Levine	University of Southern California	Mutagen Sensitivity in Familial CRC.	C-LA-0499-01
Noralane Lindor	Mayo Clinic	CFRCCS Microsatellite Instability Project (aka: The Familial Colorectal Neoplasia Collaborative Group).	C-MA-0499-02
Polly Newcomb	Fred Hutchinson Cancer Research Center	Association of CRC with Vitamin D Receptor Gene Polymorphism and Lifetime Sun Exposure.	C-SE-0899-01
Polly Newcomb	Fred Hutchinson Cancer Research Center	Hormone Replacement Therapy and Large Bowel Cancer Risk.	C-SE-0899-02
Steven Thibodeau	Mayo Clinic	Analysis of MSI markers and correlation with IHC in patients with colorectal and other cancers.	C-MA-0499-02-E03
--1998--			
Steve Gallinger	Mount Sinai Hospital, University of Toronto	Genetic Predisposition to CRC Caused by Weakly Penetrant APC Alleles.	C-TO-1298-01
Karen Glanz	Cancer Research Center of Hawaii, University of Hawaii at Manoa	Influencing Early Detection and DNA Testing in Families with CRC.	C-HA-1298-01
--1997--			
John Potter	Fred Hutchinson Cancer Research Center	Creation of a Permanent Genetics Resource at the CFRCCS.	C-SE-0097-01CS

CRC - colorectal cancer; HNPCC - hereditary non-polyposis colorectal cancer